DMD #60061 TITLE: Absorption, metabolism and excretion of oral 14 C radiolabeled ibrutinib: An open-label, phase I, single-dose study in healthy men Authors: Ellen Scheers, Laurent Leclercq, Jan de Jong, Nini Bode, Marc Bockx, Aline Laenen, Filip Cuyckens , Donna Skee, Joe Murphy, Juthamas Sukbuntherng, Geert Mannens Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium (E.S., L.L., M.B., A.L., F.C., G.M.); Clinical Pharmacology, Janssen R&D, San Diego, CA, USA (J.D.J.); Pre-Clinical Project Development, Janssen R&D, Beerse, Belgium (N.B.); Clinical Pharmacology, Janssen R&D, Raritan, NJ, US (D.S., J.M.); Pharmacyclics, Sunnyvale, CA, USA (J.S.); This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 8, 2014 as DOI: 10.1124/dmd.114.060061 at ASPET Journals on March 1, 2016 dmd.aspetjournals.org Downloaded from